By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...